CYTR Plunges, FDA Nod For AMGN, Shire, SCMP Gives Up On Cobiprostone

Shares of CytRx Corp. (CYTR) plunged over 67% in after-hours on Monday, following disappointing results from the company's phase III clinical trial of Aldoxorubicin in patients with relapsed or refractory soft tissue sarcomas.

from RTT - Biotech http://ift.tt/29zSPrO
via IFTTT